QQQ   275.83 (+1.54%)
AAPL   115.09 (+3.50%)
MSFT   204.54 (+0.92%)
FB   282.22 (+5.44%)
GOOGL   1,556.76 (+3.04%)
AMZN   3,198.46 (+1.13%)
TSLA   413.52 (+1.85%)
NVDA   519.93 (+2.94%)
BABA   309.67 (+0.56%)
CGC   18.38 (+0.22%)
GE   7.39 (-0.40%)
MU   50.28 (+0.56%)
AMD   77.79 (+1.82%)
T   26.83 (+1.25%)
F   7.96 (+3.38%)
ACB   3.84 (+0.26%)
GILD   57.43 (-2.20%)
NFLX   482.25 (-0.82%)
NIO   30.40 (+10.51%)
BA   147.25 (-0.60%)
DIS   120.08 (+1.36%)
QQQ   275.83 (+1.54%)
AAPL   115.09 (+3.50%)
MSFT   204.54 (+0.92%)
FB   282.22 (+5.44%)
GOOGL   1,556.76 (+3.04%)
AMZN   3,198.46 (+1.13%)
TSLA   413.52 (+1.85%)
NVDA   519.93 (+2.94%)
BABA   309.67 (+0.56%)
CGC   18.38 (+0.22%)
GE   7.39 (-0.40%)
MU   50.28 (+0.56%)
AMD   77.79 (+1.82%)
T   26.83 (+1.25%)
F   7.96 (+3.38%)
ACB   3.84 (+0.26%)
GILD   57.43 (-2.20%)
NFLX   482.25 (-0.82%)
NIO   30.40 (+10.51%)
BA   147.25 (-0.60%)
DIS   120.08 (+1.36%)
QQQ   275.83 (+1.54%)
AAPL   115.09 (+3.50%)
MSFT   204.54 (+0.92%)
FB   282.22 (+5.44%)
GOOGL   1,556.76 (+3.04%)
AMZN   3,198.46 (+1.13%)
TSLA   413.52 (+1.85%)
NVDA   519.93 (+2.94%)
BABA   309.67 (+0.56%)
CGC   18.38 (+0.22%)
GE   7.39 (-0.40%)
MU   50.28 (+0.56%)
AMD   77.79 (+1.82%)
T   26.83 (+1.25%)
F   7.96 (+3.38%)
ACB   3.84 (+0.26%)
GILD   57.43 (-2.20%)
NFLX   482.25 (-0.82%)
NIO   30.40 (+10.51%)
BA   147.25 (-0.60%)
DIS   120.08 (+1.36%)
QQQ   275.83 (+1.54%)
AAPL   115.09 (+3.50%)
MSFT   204.54 (+0.92%)
FB   282.22 (+5.44%)
GOOGL   1,556.76 (+3.04%)
AMZN   3,198.46 (+1.13%)
TSLA   413.52 (+1.85%)
NVDA   519.93 (+2.94%)
BABA   309.67 (+0.56%)
CGC   18.38 (+0.22%)
GE   7.39 (-0.40%)
MU   50.28 (+0.56%)
AMD   77.79 (+1.82%)
T   26.83 (+1.25%)
F   7.96 (+3.38%)
ACB   3.84 (+0.26%)
GILD   57.43 (-2.20%)
NFLX   482.25 (-0.82%)
NIO   30.40 (+10.51%)
BA   147.25 (-0.60%)
DIS   120.08 (+1.36%)
Log in
NASDAQ:MOR

MorphoSys Stock Forecast, Price & News

$25.29
+0.48 (+1.93 %)
(As of 10/29/2020 12:00 PM ET)
Add
Compare
Today's Range
$24.84
Now: $25.29▼
$25.30
50-Day Range N/A
52-Week Range
$18.21
Now: $25.29▼
$37.96
Volume3,591 shs
Average Volume108,705 shs
Market Capitalization$3.33 billion
P/E Ratio43.60
Dividend YieldN/A
Beta0.95
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys' investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.00 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MOR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.morphosys.com
Phone49 89 89927 0
Employees572

Debt

Debt-to-Equity Ratio0.07
Current Ratio5.41
Quick Ratio5.32

Price-To-Earnings

Trailing P/E Ratio43.60
Forward P/E Ratio87.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$80.43 million
Price / Sales41.37
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.49 per share
Price / Book7.25

Profitability

EPS (Most Recent Fiscal Year)($0.91)
Net Income$-115,380,000.00
Net Margins23.07%
Return on Equity12.46%
Return on Assets7.11%

Miscellaneous

Outstanding Shares131,560,000
Market Cap$3.33 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$25.29
+0.48 (+1.93 %)
(As of 10/29/2020 12:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MorphoSys (NASDAQ:MOR) Frequently Asked Questions

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for MorphoSys.

How were MorphoSys' earnings last quarter?

MorphoSys AG (NASDAQ:MOR) posted its earnings results on Wednesday, August, 5th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.03. The business had revenue of $20.26 million for the quarter, compared to analyst estimates of $10.84 million. MorphoSys had a return on equity of 12.46% and a net margin of 23.07%.
View MorphoSys' earnings history.

Are investors shorting MorphoSys?

MorphoSys saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 272,500 shares, an increase of 27.4% from the September 15th total of 213,900 shares. Based on an average trading volume of 79,700 shares, the days-to-cover ratio is currently 3.4 days.
View MorphoSys' Short Interest.

Who are some of MorphoSys' key competitors?

Some companies that are related to MorphoSys include Elanco Animal Health (ELAN), GRIFOLS S A/S (GRFS), Myokardia (MYOK), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Mirati Therapeutics (MRTX), Ascendis Pharma A/S (ASND), CureVac B.V. (CVAC), Jazz Pharmaceuticals (JAZZ), Galapagos (GLPG), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR).
View all competitors.

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 55)
  • Mr. Jens H. Holstein, CFO & Member of the Management Board (Age 57)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 58)
  • Mr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 48)
  • Mr. Klaus De Wall, Head of Accounting & Tax

When did MorphoSys IPO?

(MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners acted as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

How do I buy shares of MorphoSys?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $24.99.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $3.29 billion and generates $80.43 million in revenue each year. The company earns $-115,380,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. MorphoSys employs 572 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.com.

How can I contact MorphoSys?

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The company can be reached via phone at 49 89 89927 0 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.